Atrial Fibrillation, Paroxysmal or Persistent
Conditions
Keywords
atrial fibrillation, secretoneurin, catheter ablation, electrical cardio version
Brief summary
Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.
Detailed description
The aim of the study is to sample SN before and after catheter ablation (CA) for atrial fibrillation (Afib) to predict the recurrence after CA. Also, the uric acid/albumin ratio will be assessed as a marker of Afib recurrence. Since the uric acid/albumin ratio has been shown to be predictive of Afib in patients with myocardial infarction moreover incidence of atrial fibrillation is higher in patients with gout. As a side branch marker for silent brain injury, neuron-specific enolase (NSE) and protein S100B will be evaluated. NSE showed in small trials a significant increase after catheter ablation, as well as S100B. The prognostic power is not clear yet. From the systematic review, the most powerful predictors seem to be N-terminal (NT)-prohormone B-type natriuretic peptide (NT-Pro-BNP/BNP), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and Carboxy-terminal telopeptide of collagen type I. Biomarkers are divided into 3 main types: congestion, inflammation, and renal function. Patients will be enrolled before catheter ablation/electrical cardioversion for Afib after signing IS, and the blood sampling will be performed the day before and the day after catheter ablation. In the electric cardioversion arm, the blood sampling will be performed before electrical cardioversion and 2h after the cardioversion before discharge. Patients will be followed for recurrency - all patients will have a 24-hour ECG Holter and External loop recorder (MDT) for two weeks after the three months of the blanking period. Clinical outpatient control will ensue in the 4th, eighth,12, and 24 months.
Interventions
PROCEDURECatheter ablation and/or electrical cardioversion
Catheter ablation and/or electrical cardio version are procedures intended to treat atrial fibrillation.
Sponsors
University Hospital Ostrava
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Masking description
No masking will be used in the study.
Intervention model description
The study subjects will be enrolled in one group.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Atrial fibrillation (Afib); (paroxysmal, persistent) * Patients indicated for catheter ablation and/or electrical cardioversion * Signed informed consent
Exclusion criteria
* Longstanding or permanent atrial fibrillation * Severe mitral regurgitation * Heart failure with a permanently reduced ejection fraction * Cerebral ischaemic stroke in \< 3 months * Severe kidney injury * Severe renal insufficiency * Hepatic insufficiency limiting biomarker sampling * Myocardial infarction \< 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Atrial fibrillation recurrence based on secretoneurin levels | 24 months | Atrial fibrillation recurrence based on secretoneurin levels will be assessed |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Brain injury detection | 24 months | Brain injury will be detected using serum protein S100B and neuron specific enolase. |
Countries
Czechia
Contacts
Primary ContactJiří Hynčica
Outcome results
None listed